Ezetimibe prevents hepatic steatosis induced by a high-fat but not a high-fructose diet

American Journal of Physiology - Endocrinology and Metabolism

Volumn 305, Issue 2, 2013, Pages

  Ushio, Masateru ^a   Nishio, Yoshihiko ^b   Sekine, Osamu ^a   Nagai, Yoshio ^c   Maeno, Yasuhiro ^d   Ugi, Satoshi ^a   Yoshizaki, Takeshi ^a   Morino, Katsutaro ^a   Kume, Shinji ^a   Kashiwagi, Atsunori ^a   Maegawa, Hiroshi ^a  

^a SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

^b KAGOSHIMA UNIVERSITY   (Japan)

^c ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE HOSPITAL   (Japan)

^d Higashi ohmi General Medical Center   (Japan)

Author keywords

Ezetimibe; Hepatic and intestinal lipogenesis; NAFLD

Indexed keywords

APOLIPOPROTEIN B48; CHOLESTEROL; EZETIMIBE; FATTY ACID SYNTHASE; FATTY ACID TRANSPORTER 4; FRUCTOSE; GLUCOSE; INSULIN; LIVER X RECEPTOR ALPHA; PYRUVIC ACID; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL SYNTHESIS; CONTROLLED STUDY; DIET; EPIDIDYMIS FAT; FATTY ACID TRANSPORT; FATTY LIVER; GEL MOBILITY SHIFT ASSAY; GENE EXPRESSION; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE TEST; HIGH FRUCTOSE DIET; HYPERINSULINEMIA; IMMUNOBLOTTING; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; INSULIN TOLERANCE TEST; INTESTINE CELL; LIPID DIET; LIPID METABOLISM; LIPID STORAGE; LIPOGENESIS; LIPOPROTEIN METABOLISM; MALE; MOUSE; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

EZETIMIBE; HEPATIC AND INTESTINAL LIPOGENESIS; NAFLD;

ANIMALS; ANTICHOLESTEREMIC AGENTS; APOLIPOPROTEINS B; AZETIDINES; AZO COMPOUNDS; BLOTTING, WESTERN; CELL NUCLEUS; DIET; DIET, HIGH-FAT; ELECTROPHORETIC MOBILITY SHIFT ASSAY; ENTEROCYTES; FATTY LIVER; FRUCTOSE; GLUCOSE TOLERANCE TEST; INTESTINES; LIPID METABOLISM; LIPOPROTEINS; LIVER; MALE; MICE; MICE, INBRED CBA; PYRUVIC ACID; REAL-TIME POLYMERASE CHAIN REACTION; RNA;

EID: 84880144855     PISSN: 01931849     EISSN: 15221555     Source Type: Journal    
DOI: 10.1152/ajpendo.00442.2012     Document Type: Article

References (44)

1. Adams LA, Lindor KD. Nonalcoholic fatty liver disease. Ann Epidemiol 17: 863-869, 2007.
2. Altmann SW, Davis HR Jr, Zhu LJ, Yao X, Hoos LM, Tetzloff G, Iyer SP, Maguire M, Golovko A, Zeng M, Wang L, Murgolo N, Graziano MP. Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption. Science 303: 1201-1204, 2004.
3. Bełtowski J. Liver X receptors (LXR) as therapeutic targets in dyslipidemia. Cardiovasc Ther 26: 297-316, 2008.
4. Bligh EG, Dyer WJ. A rapid method of total lipid extraction and purification. Can J Biochem Physiol 37: 911-917, 1959.
5. Byrne CD. Non-alcoholic fatty liver disease, insulin resistance and ectopic fat: a new problem in diabetes management. Diabet Med 29: 1098-107, 2012.
6. Collison KS, Saleh SM, Bakheet RH, Al-Rabiah RK, Inglis AL, Makhoul NJ, Maqbool ZM, Zaidi MZ, Al-Johi MA, Al-Mohanna FA. Diabetes of the liver: the link between nonalcoholic fatty liver disease and HFCS-55. Obesity 17: 2003-2013, 2009.
7. Curtin A, Deegan P, Owens D, Collins P, Johnson A, Tomkin GH. Alterations in apolipoprotein B-48 in the postprandial state in NIDDM. Diabetologia 37: 1259-1264, 1994.
8. Deivanayagam S, Mohammed BS, Vitola BE, Naguib GH, Keshen TH, Kirk EP, Klein S. Nonalcoholic fatty liver disease is associated with hepatic and skeletal muscle insulin resistance in overweight adolescents. Am J Clin Nutr 88: 257-262, 2008.
9. Dentin R, Girard J, Postic C. Carbohydrate responsive element binding protein (ChREBP) and sterol regulatory element binding protein-1c (SREBP-1c): two key regulators of glucose metabolism and lipid synthesis in liver. Biochimie 87: 81-86, 2005.
10. Deushi M, Nomura M, Kawakami A, Haraguchi M, Ito M, Okazaki M, Ishii H, Yoshida M. Ezetimibe improves liver steatosis and insulin resistance in obese rat model of metabolic syndrome. FEBS Lett 581: 5664-5670, 2007.
11. Enjoji M, Machida K, Kohjima M, Kato M, Kotoh K, Matsunaga K, Nakashima M, Nakamuta M. NPC1L1 inhibitor ezetimibe is a reliable therapeutic agent for non-obese patients with nonalcoholic fatty liver disease. Lipids Health Dis 9: 29, 2010.
12. Ferre P, Foufelle F. SREBP-1c transcription factor and lipid homeostasis: clinical perspective. Horm Res 68: 72-82, 2007.
13. Foretz M, Guichard C, Ferre P, Foufelle F. Sterol regulatory element binding protein-1c is a major mediator of insulin action on the hepatic expression of glucokinase and lipogenesis-related genes. Proc Natl Acad Sci USA 96: 12737-12742, 1999.
14. Foufelle F, Ferre P. New perspectives in the regulation of hepatic glycolytic and lipogenic genes by insulin and glucose: a role for the transcription factor sterol regulatory element binding protein-1c. Biochem J 366: 377-391, 2002.
15. Guo Q, Avramoglu RK, Adeli K. Intestinal assembly and secretion of highly dense/lipid-poor apolipoprotein B48-containing lipoprotein particles in the fasting state: evidence for induction by insulin resistance and exogenous fatty acids. Metabolism 54: 689-697, 2005.
16. Haidari M, Leung N, Mahbub F, Uffelman KD, Kohen-Avramoglu R, Lewis GF, Adeli K. Fasting and postprandial overproduction of intestinally derived lipoproteins in an animal model of insulin resistance. Evidence that chronic fructose feeding in the hamster is accompanied by enhanced intestinal de novo lipogenesis and apoB48-containing lipoprotein overproduction. J Biol Chem 277: 31646-31655, 2002.
17. Herrmann T, van der Hoeven F, Grone HJ, Stewart AF, Langbein L, Kaiser I, Liebisch G, Gosch I, Buchkremer F, Drobnik W, Schmitz G, Stremmel W. Mice with targeted disruption of the fatty acid transport protein 4 gene show features of lethal restrictive dermopathy. J Cell Biol 161: 1105-1115, 2003.
18. Hsieh J, Hayashi AA, Webb J, Adeli K. Postprandial dyslipidemia in insulin resistance: mechanisms and role of intestinal insulin sensitivity. Atheroscler Suppl 9: 7-13, 2008.
19. Hudgins LC, Hellerstein MK, Seidman CE, Neese RA, Tremaroli JD, Hirsch J. Relationship between carbohydrate-induced hypertriglyceridemia and fatty acid synthesis in lean and obese subjects. J Lipid Res 41: 595-604, 2000.
20. James OF, Day CP. Non-alcoholic steatohepatitis (NASH): a disease of emerging identity and importance. J Hepatol 29: 495-501, 1998.
21. Janowski BA, Willy PJ, Devi TR, Falck JR, Mangelsdorf DJ. An oxysterol signalling pathway mediated by the nuclear receptor LXR alpha. Nature 383: 728-731, 1996.
22. Kawaguchi T, Takenoshita M, Kabashima T, Uyeda K. Glucose and cAMP regulate the L-type pyruvate kinase gene by phosphorylation/ dephosphorylation of the carbohydrate response element binding protein. Proc Natl Acad Sci USA 98: 13710-13715, 2001.
23. Labonté ED, Camarota LM, Rojas JC, Jandacek RJ, Gilham DE, Davies JP, Ioannou YA, Tso P, Hui DY, Howles PN. Reduced absorption of saturated fatty acids and resistance to diet-induced obesity and diabetes by ezetimibe-treated and Npc1l1-/-mice. Am J Physiol Gastrointest Liver Physiol 295: G776-G783, 2008.
24. Lê KA, Ith M, Kreis R, Faeh D, Bortolotti M, Tran C, Boesch C, Tappy L. Fructose overconsumption causes dyslipidemia and ectopic lipid deposition in healthy subjects with and without a family history of type 2 diabetes. Am J Clin Nutr 89: 1760-1765, 2009.
25. Lee AH, Scapa EF, Cohen DE, Glimcher LH. Regulation of hepatic lipogenesis by the transcription factor XBP1. Science 320: 1492-1496, 2008.
26. Lehmann JM, Kliewer SA, Moore LB, Smith-Oliver TA, Oliver BB, Su JL, Sundseth SS, Winegar DA, Blanchard DE, Spencer TA, Willson TM. Activation of the nuclear receptor LXR by oxysterols defines a new hormone response pathway. J Biol Chem 272: 3137-3140, 1997.
27. Leung N, Naples M, Uffelman K, Szeto L, Adeli K, Lewis GF. Rosiglitazone improves intestinal lipoprotein overproduction in the fat-fed Syrian Golden hamster, an animal model of nutritionally-induced insulin resistance. Atherosclerosis 174: 235-241, 2004.
28. Lim JS, Mietus-Snyder M, Valente A, Schwarz JM, Lustig RH. The role of fructose in the pathogenesis of NAFLD and the metabolic syndrome. Nat Rev Gastroenterol Hepatol 7: 251-264, 2010.
29. Muraoka T, Aoki K, Iwasaki T, Shinoda K, Nakamura A, Aburatani H, Mori S, Tokuyama K, Kubota N, Kadowaki T, Terauchi Y. Ezetimibe decreases SREBP-1c expression in liver and reverses hepatic insulin resistance in mice fed a high-fat diet. Metabolism 60: 617-628, 2011.
30. Nagai Y, Yonemitsu S, Erion DM, Iwasaki T, Stark R, Weismann D, Dong J, Zhang D, Jurczak MJ, Löffler MG, Cresswell J, Yu XX, Murray SF, Bhanot S, Monia BP, Bogan JS, Samuel V, Shulman GI. The role of peroxisome proliferator-activated receptor gamma coactivator-1 beta in the pathogenesis of fructose-induced insulin resistance. Cell Metab 9: 252-264, 2009.
31. Nagata R, Nishio Y, Sekine O, Nagai Y, Maeno Y, Ugi S, Maegawa H, Kashiwagi A. Single nucleotide polymorphism at the promoter region of SREBP-1c associates with genetic defect of fructose-induced hepatic lipogenesis. J Biol Chem 9: 29031-29042, 2004.
32. Naples M, Baker C, Lino M, Iqbal J, Hussain MM, Adeli K. Ezetimibe ameliorates intestinal chylomicron overproduction and improves glucose tolerance in a diet-induced hamster model of insulin resistance. Am J Physiol Gastrointest Liver Physiol 302: G1043-G1052, 2012.
33. Nomura M, Ishii H, Kawakami A, Yoshida M. Inhibition of hepatic Niemann-Pick C1-like 1 improves hepatic insulin resistance. Am J Physiol Endocrinol Metab 297: E1030-E1038, 2009.
34. Otokozawa S, Ai M, Diffenderfer MR, Asztalos BF, Tanaka A, Lamon-Fava S, Schaefer EJ. Fasting and postprandial apolipoprotein B-48 levels in healthy, obese, and hyperlipidemic subjects. Metabolism 58: 1536-1542, 2009.
35. Oyadomari S, Harding HP, Zhang Y, Oyadomari M, Ron D. Dephosphorylation of translation initiation factor 2alpha enhances glucose tolerance and attenuates hepatosteatosis in mice. Cell Metab 7: 520-532, 2008.
36. Pessayre D. Role of mitochondria in nonalcoholic fatty liver disease. J Gastroenterol Hepatol 22: S20-S27, 2007.
37. Phillips C, Murugasu G, Owens D, Collins P, Johnson A, Tomkin GH. Improved metabolic control reduces the number of postprandial apolipoprotein B-48-containing particles in type 2 diabetes. Atherosclerosis 148: 283-291, 2000.
38. Saltiel AR, Kahn CR. Insulin signalling and the regulation of glucose and lipid metabolism. Nature 414: 799-806, 2001.
39. Sandoval JC, Nakagawa-Toyama Y, Masuda D, Tochino Y, Nakaoka H, Kawase R, Yuasa-Kawase M, Nakatani K, Inagaki M, Tsubakio-Yamamoto K, Ohama T, Matsuyama A, Nishida M, Ishigami M, Komuro I, Yamashita S. Molecular mechanisms of ezetimibe-induced attenuation of postprandial hypertriglyceridemia. J Atheroscler Thromb 17: 914-924, 2010.
40. Schwarz JM, Neese RA, Turner S, Dare D, Hellerstein MK. Short-term alterations in carbohydrate energy intake in humans. Striking effects on hepatic glucose production, de novo lipogenesis, lipolysis, and wholebody fuelselection. J Clin Invest 96: 2735-2743, 1995.
41. Shimomura I, Bashmakov Y, Horton JD. Increased levels of nuclear SREBP-1c associated with fatty livers in two mouse models of diabetes mellitus. J Biol Chem 274: 30028-30032, 1999.
42. Stahl A, Hirsch DJ, Gimeno RE, Punreddy S, Ge P, Watson N, Patel S, Kotler M, Raimondi A, Tartaglia LA, Lodish HF. Identification of the major intestinal fatty acid transport protein. Mol Cell 4: 299-308, 1999.
43. Tetri LH, Basaranoglu M, Brunt EM, Yerian LM, Neuschwander-Tetri BA. Severe NAFLD with hepatic necroinflammatory changes in mice fed trans fats and a high-fructose corn syrup equivalent. Am J Physiol Gastrointest Liver Physiol 295: G987-G995, 2008.
44. Unger RH, Clark GO, Scherer PE, Orci L. Lipid homeostasis, lipotoxicity, and themetabolic syndrome. Biochim Biophys Acta 1801: 209-214, 2010.